Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia
1 finding from 1 review
Adverse events (at 12 weeks) · adults with insomnia
1 finding from 1 review
PSG sleep outcomes (at 12 weeks) · adults with insomnia
1 finding from 1 review
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Efficacy as a continuous outcome · patients with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Participant perception of change with treatment · adult men with premature ejaculation
SSRI probably leads to higher participant perception of change with treatment compared with placebo (moderate certainty).
1 finding from 1 review
Participant satisfaction with intercourse · adult men with premature ejaculation
SSRI probably leads to higher participant satisfaction with intercourse compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult men with premature ejaculation
SSRI may leads to higher study withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Perceived control over ejaculation · adult men with premature ejaculation
SSRI probably leads to higher perceived control over ejaculation compared with placebo (moderate certainty).
1 finding from 1 review
Participant distress about PE · adult men with premature ejaculation
SSRI probably leads to higher participant distress about PE compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adult men with premature ejaculation
SSRI probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
IELT · adult men with premature ejaculation
1 finding from 1 review
Migraine frequency Number of attacks · patients for whom migraine preventive interventions are indicated
1 finding from 1 review
Migraine duration Hours · patients for whom migraine preventive interventions are indicated
1 finding from 1 review